ICU Medical (ICUI) Q4 2020 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2020 earnings summary
6 Nov, 2026Executive summary
Revenue grew to $1.271B in 2020 from $1.266B in 2019 despite COVID-19 disruption; stronger Infusion Systems sales offset weaker Consumables and IV Solutions demand.
Infusion pump growth included the first annual increase in U.S. pump sales since the 2017 Hospira acquisition; free cash flow was described as the strongest in company history.
Management cited improved market position, product mix and customer relationships as foundations for 2021, while retaining a conservative capital structure.
Financial highlights
FY2020 revenue $1,271.0M vs. $1,266.2M in 2019; operating income $98.2M vs. $107.4M; net income $86.9M vs. $101.0M.
Diluted EPS was $4.02 vs. $4.69 in 2019; cash from operations increased to $222.8M from $101.9M.
Gross profit was $461.5M and gross margin 36.3% vs. 37.3% in 2019; lower IV Solutions manufacturing volumes and unfavorable consumables mix weighed on margin.
Operating expenses included $28.4M in restructuring, strategic transaction and integration costs, plus a $9.0M increase in the Pursuit earn-out fair value.
Outlook and guidance
2021 capital expenditures estimated at $75M-$85M, mainly for manufacturing machinery and equipment and infusion pumps placed with customers outside the U.S.
Existing cash, cash equivalents and expected operating cash generation were expected to fund operations for the next 12 months; management retained the $150M revolving facility for flexibility.
Management anticipated a gradual return toward normal hospital utilization in 2021 and expected growth products, including ChemoLock, ChemoClave and ClearGuard, to support Consumables.
Several critical new regulatory filings were planned for 2021; management expressed hope for a more normal operating environment as vaccines and therapies improved the pandemic outlook.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018